Takeda’s Zasocitinib Shows Strong Efficacy in Hard-to-Treat Psoriasis Sites — Takeda Pharmaceutical Company Limited

Event summary

Takeda’s Phase 3 studies show zasocitinib achieved high skin clearance rates in hard-to-treat psoriasis areas like scalp, nails, palms, and soles.
70% of patients treated with zasocitinib achieved sPGA 0/1 (clear or almost clear skin) at week 16.
Takeda plans to submit a New Drug Application for plaque psoriasis beginning this fiscal year.
Zasocitinib is also being evaluated in Phase 3 studies for psoriatic arthritis and Phase 2 studies for Crohn’s disease, ulcerative colitis, vitiligo, and hidradenitis suppurativa.

The big picture

Takeda’s positive Phase 3 data for zasocitinib reinforces the potential of selective TYK2 inhibition in treating moderate-to-severe plaque psoriasis, particularly in challenging areas. The company’s plans to submit a New Drug Application this fiscal year highlight its aggressive strategy to capitalize on unmet needs in psoriasis treatment. Success could position zasocitinib as a leading oral therapy, expanding Takeda’s portfolio in inflammatory diseases.

What we're watching

Regulatory Approval: The pace at which Takeda secures regulatory approval for zasocitinib in plaque psoriasis will determine its market entry timing and competitive positioning.
Clinical Pipeline Expansion: Whether zasocitinib’s success in psoriasis translates to other indications like psoriatic arthritis, Crohn’s disease, and ulcerative colitis could expand its commercial potential.
Market Competition: How zasocitinib will differentiate itself against existing TYK2 inhibitors and other treatments for hard-to-treat psoriasis sites.